Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
Divi's Laboratories is currently trading at Rs. 743.60, up by 63.45 points or 9.33% from its previous closing of Rs. 680.15 on the BSE.
The scrip opened at Rs. 681.25 and has touched a high and low of Rs. 816.15 and Rs. 681.25 respectively. So far 3771499 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1380.00 on 16-Sep-2016 and a 52 week low of Rs. 533.10 on 29-May-2017.
Last one week high and low of the scrip stood at Rs. 816.15 and Rs. 648.15 respectively. The current market cap of the company is Rs. 20234.02 crore.
The promoters holding in the company stood at 52.07%, while institutions and non-institutions held 31.42% and 16.51% respectively.
The United States Food & Drug Administration (USFDA) is all set to lift the Import Alert 99-32 imposed on Divi’s Laboratories Unit-II at Visakhapatnam. The USFDA issued an Import Alert under clauses 99-32 and 66-40 in March of 2017 and a warning letter in May of 2017 for the company’s Vishakhapatnam facility.
The company filed detailed responses and given updates to the Form-483 and the warning letter within the stipulated time. Divi’s Laboratories, along with its external consultants, specialists and subject matter experts, has taken up appropriate remediation measures to address the concerns raised by USFDA. The company awaits further action from USFDA in this regard. The above development illustrates the company’s commitment to work closely with the USFDA and its efforts towards compliance to cGMP regulations.
Divi’s Laboratories focussed on developing new processes for the production of Active Pharma Ingredients (APIs) & Intermediates. The company in a matter of short time expanded its breadth of operations to provide complete turnkey solutions to the domestic Indian pharmaceutical industry.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1532.85 |
| Dr. Reddys Lab | 5812.50 |
| Cipla | 1403.90 |
| Zydus Lifesciences | 1104.45 |
| Lupin | 1661.90 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
